Technology Assessment Examples from Germany and some thoughts about the need for multilateral TA




Dr. Andreas Stamm 16.11.2022



TA in Germany: The Institutional Setting



Institute for Technology
Assessment and Systems Analysis (ITAS)



Technology Assessment in Germany: Example



Example 1: Nanotechnology in the early 2000s


Emerging Technology – only visions about prospective use, but no knowledge and data

Hype as regards options for nano-manufacturing, new therapies for cancer, etc... vs distopian expectations ("grey" goo)

Possible need for public funding and legal regulation – but lack of clarity clear how policy making should take it up

The "Gray Goo" Nightmare





Nanotechnology TA study on behalf of the German Government



- Scanning the international discussion on Nanotechnology (Science and governmental programs) with regard to state of research, prospective applications and problematic issues
- Commissioning expert studies on specific aspects (Nano in medicine, Nano for cosmetic products ...)
- Workshop of salient experts and stakeholders in Germany: Sorting out areas of consensus and dissensus as regards chances and risks (separating hype fom reliable expectations)
- Public opinion survey on Nanotechnology

Composition of the Expert Group



- Industrial engineering (automobile, energy, construction, chemical, aerospace, textile)
- Information and communication technologies (optical electronics, CPU design, quantum computing)
- Life sciences (microbiology, biotechnology, bioengineering, bioinformatics, food and nutrition, cosmetics)
- Cross cutting expertise: public perceptions, ethics, law

Impacts of the TA Study on Nanotechnology



- Outcome: Recommendations for a German Nanotechnology Research Progamme
- Defining focus areas of research (New Materials for industrial applications)
- Setting up an accompanying research programme on health effects of Nano Particles (invading of particles the brain-blood-barrier)
 - > Early political up-take of risk issues,
 - > Reducing the "grey goo" debate to its rational core
- Nano-Particles and health issue proved to be the longstanding issue of the debate
- Regulation by European Paliament, applying the REACH framework: Registration, Evaluation, Authorisation and Restriction of chemicals

Heuristics of fear or heuristics of hope? Gene Editing



In July 2018, the European Court of Justice classifies organisms created by genome editing techniques (such as CRISPR-Cas9) as genetically modified organisms (GMOs) within the meaning of the EU GMO Directive.

A technical-legal ruling with far-reaching consequences in the Global South:

- All future innovation cycles in the field of gene editing in the European Union have to follow the strict regulations for GMO crops. This process is lengthy (4-6 years) and costly (7-15 million euros).
- All crops which involve Gene Editing techniques have to be labelled as GMO crops. On the European markets this basically excludes commercialization
- Developing countries have to chose to either abstain from using gene editing or abstain from export agricultural products to the EU

Heuristics of fear or heuristics of hope? Gene Editing



The ruling of the EU Court of Justice was not based on a serious TA exercise, but rather on an ad hoc understanding of possible risks of the new technology

It has its normative roots in the precautionary principle, as laid down in Article 191 of the European Treaty. The precautionary principle calls for preventive actions in the face of uncertain information about risks.

The ad hoc assessment of possible risks of gene editing has been rejected by most of the scientific community.

As decisions about technologies have a global reach, we need multilateral modes of TA, which take into considerations different assessments of opportunities and risks!



Thanks for your attention!

andreas.stamm@idos-research.de

Contact

German Institute of Development and Sustainability (IDOS)

Tulpenfeld 6

53113 Bonn

Deutschland

Telefon +49 228 94 927-0

Telefax +49 228 94 927-130

presse@idos-research.de

www.idos-research.de



